Mesothelioma Life Expectancy by Stage: Stage 1 Through Stage 4 Survival Data

Mesothelioma life expectancy by stage spans approximately 21 to 23 months reported median overall survival for stage 1, 19 to 20 months for stage 2, 14 to 18 months for stage 3, and 10 to 13 months for stage 4 in pleural mesothelioma registry analyses, based on data from the National Cancer Institute (NCI) and the American Cancer Society (ACS) [1, 4]. These are population medians, not individual predictions, and most figures reflect cohorts diagnosed before routine first-line immunotherapy with nivolumab plus ipilimumab.

Key takeaways

• Stage 1 pleural mesothelioma: reported median overall survival approximately 21 to 23 months, with 5-year relative survival near 24 percent for the SEER localized category [1, 4].
• Stage 4 pleural mesothelioma: reported median overall survival approximately 10 to 13 months, with 5-year relative survival approximately 7 percent for the SEER distant category [1, 4].
• Cell type (epithelioid versus sarcomatoid or biphasic) can shift reported outcomes within a single stage as much as stage itself [1].
• Peritoneal mesothelioma treated with cytoreductive surgery and HIPEC at high-volume centers has reached published median survival of 50 to 60 months in selected cohorts [1, 3].
• US registry data typically lag clinical practice by 5 to 10 years and predate the addition of immunotherapy to the first-line setting [1].

For broader context on what shapes outcomes after a diagnosis, see the parent overview on mesothelioma prognosis and life expectancy, which positions stage as one of several prognostic factors alongside cell type, treatment eligibility, age, and overall health.

Mesothelioma is a rare cancer that develops in the thin tissue layers (mesothelium) lining the lungs, abdomen, heart, or testicles, almost always after past inhalation or ingestion of asbestos fibers. When patients and families ask about life expectancy, they are typically asking how published survival statistics map onto the disease stage given at diagnosis. This article summarizes the reported median survival ranges for stages 1, 2, 3, and 4 of malignant mesothelioma, the staging systems behind those numbers, and the limitations every reader should understand before drawing personal conclusions from registry data.

How mesothelioma is staged

Stage describes how far the cancer has spread at the time of diagnosis and is one of the strongest predictors of reported survival in published cohorts. For mesothelioma, two main frameworks are in clinical use depending on where the cancer started [1].

TNM staging and the IMIG system for pleural mesothelioma

Pleural mesothelioma, the most common form (affecting the lung lining), is staged using the TNM (Tumor, Node, Metastasis) system maintained by the American Joint Committee on Cancer (AJCC) and originally developed in collaboration with the International Mesothelioma Interest Group (IMIG) [1, 2]. TNM combines three measurements:

• T (Tumor): how extensive the primary tumor is within the pleura and whether it has invaded nearby structures such as the diaphragm, chest wall, or mediastinum.
• N (Nodes): whether regional lymph nodes contain cancer cells.
• M (Metastasis): whether the cancer has spread to distant sites such as the contralateral lung, liver, or bone.

These T, N, and M values are grouped into stages I through IV. Stage I disease is confined to one side of the pleural cavity with no nodal involvement. Stage IV indicates distant metastasis or extensive locally advanced disease that is not surgically resectable [2].

It is important to distinguish clinical stage (assigned before surgery using imaging and biopsy) from pathological stage (assigned after surgical resection using direct tissue examination). Pathological stage is usually more accurate but is only available for patients who undergo surgery, which biases comparisons across cohorts [1].

Why peritoneal mesothelioma uses a different staging approach

Peritoneal mesothelioma (in the abdominal lining) does not fit neatly into TNM because it spreads along peritoneal surfaces rather than through discrete lymph node basins. Specialized centers commonly use the Peritoneal Cancer Index (PCI), a surgical scoring system that quantifies tumor burden across 13 abdominal regions, often combined with the AJCC TNM framework when nodal or distant disease is also present [1, 3]. Because PCI scoring is gathered intraoperatively during cytoreductive surgery, published peritoneal mesothelioma survival statistics overwhelmingly reflect outcomes in surgical candidates and may not generalize to all patients.

Reported median survival by stage at a glance

AJCC stage	Reported median overall survival (pleural)	Corresponding SEER summary stage	5-year relative survival
Stage 1	Approximately 21 to 23 months [1, 4]	Localized	Approximately 24 percent [4]
Stage 2	Approximately 19 to 20 months [1]	Regional (mixed with stage 3)	Approximately 16 percent [4]
Stage 3	Approximately 14 to 18 months [1]	Regional or Distant (mixed)	Approximately 16 percent (regional) [4]
Stage 4	Approximately 10 to 13 months [1, 4]	Distant	Approximately 7 percent [4]

The AJCC TNM stages and the SEER summary stages do not map perfectly onto each other, which is why the 5-year columns above are approximations rather than exact stage-by-stage figures. The numbers are reported aggregate outcomes, not personalized estimates.

Stage 1 mesothelioma: reported median survival ranges

Stage 1 pleural mesothelioma has a reported median overall survival of approximately 21 to 23 months in registry analyses, with selected surgical series reporting longer figures in epithelioid-histology subgroups [1, 4]. The American Cancer Society reports a 5-year relative survival rate of approximately 24 percent for "localized" pleural mesothelioma, the SEER summary stage that most closely corresponds to stage 1 [4].

Stage 1 is the earliest stage at which the disease is typically detected. The tumor is confined to the parietal pleura on one side of the chest, with no lymph node involvement and no distant spread [2]. Because early symptoms (cough, mild chest discomfort, fatigue) overlap with many benign conditions, only a small minority of patients are diagnosed at this stage. These reported figures reflect aggregate outcomes from cohorts diagnosed several years before the data were published and may not capture more recent treatment advances such as combination immunotherapy regimens.

Stage 2 mesothelioma: reported median survival ranges

Stage 2 pleural mesothelioma has a reported median overall survival of approximately 19 to 20 months in pooled registry data [1]. Five-year survival figures are more variable because the AJCC stage groupings do not map perfectly onto the SEER summary stages used in many population datasets. In ACS reporting, the "regional" SEER summary category (which encompasses much of stage 2 and parts of stage 3) shows a 5-year relative survival of approximately 16 percent [4].

Stage 2 disease describes tumor that has invaded structures adjacent to the pleura (such as the diaphragm or lung parenchyma) or involves nearby lymph nodes, while still being confined to one side of the chest [2]. Stage 2 disease is often considered for multimodal therapy combining surgery, chemotherapy, and sometimes radiation, when the patient is medically fit. Outcomes in clinical trial cohorts of stage 2 patients undergoing curative-intent surgery have been higher, although these cohorts are non-representative.

Stage 3 mesothelioma: reported median survival ranges

Stage 3 pleural mesothelioma has a reported median overall survival of approximately 14 to 18 months in published registry analyses [1]. The wide range reflects two sources of variability: whether the patient was treated at a high-volume specialty center, and whether the histology was epithelioid (more favorable) versus sarcomatoid or biphasic (less favorable).

Stage 3 disease involves locally advanced tumor with extensive invasion of chest wall, mediastinal structures, or ipsilateral lymph nodes, but no distant metastasis [2]. Surgical resectability at stage 3 depends heavily on the specific anatomic findings; some stage 3 tumors are technically resectable, while others are not. Stage 3 is also where the gap between clinical stage and pathological stage is largest, because some patients staged as 3 on imaging are upstaged to 4 at surgery [1].

Stage 4 mesothelioma: reported median survival ranges

Stage 4 pleural mesothelioma has a reported median overall survival of approximately 10 to 13 months across population datasets [1, 4]. The ACS-reported 5-year relative survival rate for "distant" SEER summary stage is approximately 7 percent [4].

Stage 4 disease has spread to distant sites, has crossed to the opposite pleural cavity, or has caused locally advanced involvement that is not amenable to surgery [2]. Treatment focuses on systemic therapy (chemotherapy and immunotherapy regimens) and palliative care to manage symptoms. The population figures above predate routine availability of nivolumab plus ipilimumab as first-line therapy, an immunotherapy combination that, in the CheckMate 743 trial, showed a median overall survival of 18.1 months for the combination versus 14.1 months for platinum-based chemotherapy in newly diagnosed unresectable pleural mesothelioma [1]. Population-level survival statistics typically lag clinical trial data by several years.

How to read survival statistics: medians, 5-year rates, and confidence intervals

Survival statistics quoted in mesothelioma articles look precise, but they conceal substantial uncertainty. A few interpretive points help readers use these numbers without overreading them:

• Median survival is not maximum survival. A median of 18 months means that half of patients in the studied cohort lived longer than 18 months and half lived shorter. The distribution typically has a long right tail, and some patients lived many years past the median in published cohorts [5].
• 5-year relative survival is the percentage of patients still alive five years after diagnosis, adjusted for deaths from causes unrelated to cancer. It is not the same as the chance any individual patient has of reaching five years.
• Confidence intervals matter. When a study reports "median survival 16 months (95% CI 14 to 18 months)," the true median for the underlying population could be anywhere in that interval. Small cohorts produce wide intervals and unstable point estimates [5].
• Registry data lag current treatment. SEER and similar registries publish 5-year survival figures from patients diagnosed five to ten years earlier. Outcomes reported today may not reflect contemporary care, particularly the addition of immunotherapy to the first-line setting [1].

Factors beyond stage that influence prognosis

Stage is the single most cited prognostic factor, but several others move outcomes meaningfully, sometimes more than stage itself [1, 6].

Cell type (epithelioid, sarcomatoid, biphasic)

Pleural mesothelioma has three main histologic subtypes, and cell type can shift reported median survival by months to years within the same stage [1]:

• Epithelioid mesothelioma accounts for roughly 60 to 70 percent of cases and carries the most favorable median survival within each stage [1].
• Sarcomatoid mesothelioma is the most aggressive subtype and is associated with median survival roughly half that of epithelioid disease at the same stage [1].
• Biphasic mesothelioma contains both epithelioid and sarcomatoid components, and reported outcomes correlate with the percentage of sarcomatoid tissue present.

Other meaningful factors include age at diagnosis, baseline performance status (an assessment of how well the patient can carry out daily activities), pulmonary function, weight loss before diagnosis, and laboratory markers such as platelet count and lactate dehydrogenase [1, 6]. Treatment eligibility, particularly fitness for multimodal therapy or clinical trials, also shifts outcomes.

How peritoneal mesothelioma survival differs from pleural

Peritoneal mesothelioma was historically treated as a uniformly poor-prognosis disease, but reported survival has shifted markedly with the wider adoption of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) at specialized centers [1, 3]. In selected surgical candidates with low PCI scores and epithelioid histology, published median survival figures from high-volume programs have reached 50 to 60 months or more, with 5-year survival rates above 50 percent in some series.

Patients who are not candidates for CRS-HIPEC (because of comorbidities, extensive disease, or unfavorable histology) typically receive systemic chemotherapy alone, and their reported median survival figures resemble or modestly exceed pleural mesothelioma statistics. The wide gap between surgical and non-surgical cohorts is why a single "peritoneal mesothelioma survival rate" can be misleading without context.

Where these statistics come from and what they do not capture

Most of the numbers in this article trace back to a small set of data sources [1, 4, 6, 7]:

• The SEER program, run by the National Cancer Institute, pools cancer registry data from a subset of US states and is the source of population-level survival statistics for mesothelioma.
• The AJCC and IMIG staging databases, which underpin the stage-grouping rules.
• Peer-reviewed analyses published in journals such as the Journal of Thoracic Oncology, which apply additional statistical methods to registry data to estimate stage-specific outcomes.
• National statistics from non-US registries, including Cancer Research UK and equivalent agencies, which sometimes report higher or lower numbers because of differences in diagnostic patterns and registry inclusion criteria.

What these sources do not capture: individual variation, evolving treatment standards, access to clinical trials, and the experience of high-volume specialty centers. They also do not cleanly separate by treatment received, which means that a "stage 3 median survival" figure mixes outcomes for patients who had surgery and patients who did not.

Frequently Asked Questions

What is the reported life expectancy for stage 1 mesothelioma?

Published registry data put the reported median overall survival for stage 1 pleural mesothelioma in the range of approximately 21 to 23 months, with a 5-year relative survival rate near 24 percent for the corresponding SEER localized category, according to NCI and ACS sources. Reported outcomes vary widely by histology, age, and treatment received [1, 4].

Can a patient survive stage 4 mesothelioma?

Some patients with stage 4 pleural mesothelioma have lived for several years after diagnosis, although the reported 5-year relative survival rate for distant-stage disease is approximately 7 percent according to ACS data. Reported survival depends heavily on histology, baseline performance status, and response to systemic therapy including newer immunotherapy regimens [1, 4].

How long do most people live after a mesothelioma diagnosis?

Across all stages combined, published median overall survival for pleural mesothelioma is commonly reported in the range of 12 to 21 months, with a roughly 12 percent 5-year relative survival rate in US registry data. Peritoneal mesothelioma cohorts treated at specialized centers with CRS-HIPEC report substantially longer figures in published series [1, 4].

Does the type of mesothelioma affect life expectancy?

Yes. Pleural and peritoneal mesothelioma have different staging frameworks and meaningfully different reported survival distributions, especially for peritoneal patients eligible for cytoreductive surgery with HIPEC. Within pleural disease, epithelioid histology is associated with longer reported survival than sarcomatoid or biphasic subtypes in published cohorts [1, 3].

What factors are associated with longer mesothelioma survival?

Reported prognostic factors include earlier stage at diagnosis, epithelioid histology, younger age, better baseline performance status, eligibility for multimodal therapy or clinical trials, and treatment at high-volume specialty centers. Laboratory markers such as platelet count and lactate dehydrogenase also carry prognostic information in published statistical models [1, 6].

Conclusion

Mesothelioma life expectancy by stage is best understood as a set of overlapping ranges drawn from registry data, surgical series, and clinical trials, rather than a single number per stage. Stage 1 disease is associated with the longest reported median survival in published cohorts, stage 4 with the shortest, and stages 2 and 3 with intermediate figures, but cell type, treatment received, and individual factors can shift outcomes substantially within each stage. Patients and families looking for situation-specific information should bring these published ranges to a conversation with a mesothelioma-experienced oncologist, who can incorporate the details that aggregate statistics cannot.

Sources

1. National Cancer Institute. Malignant Mesothelioma Treatment (PDQ): Health Professional Version. https://www.cancer.gov/types/mesothelioma/hp/mesothelioma-treatment-pdq
2. American Cancer Society. Mesothelioma Stages. https://www.cancer.org/cancer/types/malignant-mesothelioma/detection-diagnosis-staging/staging.html
3. National Cancer Institute. Malignant Mesothelioma Treatment (PDQ): Patient Version. https://www.cancer.gov/types/mesothelioma/patient/mesothelioma-treatment-pdq
4. American Cancer Society. Survival Rates for Mesothelioma. https://www.cancer.org/cancer/types/malignant-mesothelioma/detection-diagnosis-staging/survival-statistics.html
5. National Cancer Institute. Understanding Cancer Prognosis. https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis
6. National Cancer Institute SEER Program. Cancer Stat Facts: Mesothelioma. https://seer.cancer.gov/statfacts/html/meso.html
7. Cancer Research UK. Survival for mesothelioma. https://www.cancerresearchuk.org/about-cancer/mesothelioma/survival

Last reviewed: 2026-05-22

Mesothelioma Cancer Help is an independent information resource. We are not a law firm, medical provider, or patient services organization, and we do not provide legal, medical, or financial advice. Information on this site is for general educational purposes only. Always consult a qualified medical professional for questions about your health, and a licensed attorney for questions about your legal rights. If you are in a medical emergency, call 911 or go to your nearest emergency room.